Budesonide, Formoterol Fumarate Drug Combination
Showing 1 - 25 of >10,000
COPD Trial in Worldwide (Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and
Not yet recruiting
- Chronic Obstructive Pulmonary Disease
- Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
- +2 more
-
Torrance, California
- +25 more
Sep 28, 2023
Moderate Asthma Trial in São Paulo (Administration of investigation drug, Administration of comparator)
Not yet recruiting
- Moderate Asthma
- Administration of investigation drug
- Administration of comparator
-
São Paulo, BrazilEurofarma Laboratorios S.A
Feb 9, 2023
Asthma Trial in Medford (Budesonide 80 µg and Formoterol Fumarate Dihydrate 4.5 µg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation
Recruiting
- Asthma
- Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg
- +2 more
-
Medford, OregonVelocity Clinical Research
May 6, 2022
Quality of Life With Administration of Fixed Combination of
Completed
- Asthma
- Quality of Life
- Budesonide/Formoterol treated patients
-
Athens, Mesogion Ave. 152, Greece7th Pulmonary Dept, Athens Chest Hospital
Sep 7, 2022
COPD Trial in Glendale (Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA)
Recruiting
- Chronic Obstructive Pulmonary Disease
- Treatment A: BGF MDI HFO
- Treatment B: BGF MDI HFA
-
Glendale, CaliforniaResearch Site
Jan 18, 2023
COPD (COPD) Trial in Guelph (BGF MDI HFO 320/14.4/9.6µg, BGF MDI HFA 320/14.4/9.6 µg, Placebo MDI HFA)
Not yet recruiting
- COPD (Chronic Obstructive Pulmonary Disease)
- BGF MDI HFO 320/14.4/9.6μg
- +2 more
-
Guelph, Ontario, CanadaResearch Site
Oct 4, 2023
COPD (COPD) Trial in Germany (BFF, Symbicort Turbuhaler)
Completed
- Chronic Obstructive Pulmonary Disease (COPD)
- BFF
- Symbicort Turbuhaler
-
Frankfurt/Main, Germany
- +3 more
Feb 21, 2022
Real-life After Initation of Treatment With Trixeo
Not yet recruiting
- Chronic Obstructive Pulmonary Disease
- BGF (budesonide/glycopyrrolate/formoterol fumarate)
-
Acquaviva delle Fonti, Italy
- +23 more
May 8, 2023
COPD Trial in Brooklyn (Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated
Recruiting
- Chronic Obstructive Pulmonary Disease
- Treatment A (BGF MDI HFO with oral activated charcoal)
- Treatment B (BGF MDI HFA with oral activated charcoal)
-
Brooklyn, MarylandResearch Site
Aug 11, 2022
COPD Trial in Paris (Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI, Budesonide 200 µg plus formoterol 6 µg DPI,
Completed
- Chronic Obstructive Pulmonary Disease
- Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
- +2 more
-
Paris, FranceThomas Similowski
Oct 28, 2021
Asthma Trial in Rotterdam (Budesonide/Formoterol fumarate dihydrate)
Recruiting
- Asthma
- Budesonide/Formoterol fumarate dihydrate
-
Rotterdam, Zuid-Holland, NetherlandsFranciscus Gasthuis & Vlietland
Apr 14, 2023
Asthma Trial in United States (Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo)
Completed
- Asthma
- Budesonide/Formoterol fumarate dihydrate
- +2 more
-
Birmingham, Alabama
- +94 more
Aug 1, 2022
Symptom and Quality of Life in COPD by
Recruiting
- Pulmonary Disease, Chronic Obstructive
-
Nagoya, Aichi, Japan
- +16 more
Jan 17, 2023
Asthma in Children Trial in France (Budesonide Formoterol Drug Combination, nebulisation of terbutaline)
Recruiting
- Asthma in Children
- Budesonide Formoterol Drug Combination
- nebulisation of terbutaline
-
Boulogne-Billancourt, France
- +7 more
Sep 6, 2021
Asthma Trial in Worldwide (BFF MDI 160/9.6 µg BID (320/19.2µg/day), BD MDI 160 µg BID (320 µg/day))
Recruiting
- Asthma
- BFF MDI 160/9.6 μg BID (320/19.2μg/day)
- BD MDI 160 μg BID (320 μg/day)
-
Huntington Beach, California
- +52 more
Mar 9, 2023
Real-world, 52-week Prospective Study to Capture Reasons for
Not yet recruiting
- Pulmonary Disease, Chronic Obstructive (COPD)
- Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
- (no location specified)
Jun 13, 2023
Asthma Trial in Worldwide (BFF MDI 320/9.6 µg, BFF MDI 160/9.6 µg, BD MDI 320 µg)
Recruiting
- Asthma
- BFF MDI 320/9.6 μg
- +3 more
-
Saraland, Alabama
- +121 more
Aug 22, 2022
Exercise Performance Trial in Copenhagen (Symbicort, Formoterol, Placebo)
Not yet recruiting
- Exercise Performance
- Symbicort
- +3 more
-
Copenhagen, DenmarkAugust Krogh Building
Oct 23, 2023
COPD (COPD) Trial in Glendale (Treatment A, Treatment B, Treatment C)
Completed
- Chronic Obstructive Pulmonary Disease (COPD)
- Treatment A
- +2 more
-
Glendale, CaliforniaResearch Site
Apr 20, 2022
Asthma Trial (Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID, Mometasone Furoate MDI (MF MDI), Formoterol
Completed
- Asthma
- Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
- +3 more
- (no location specified)
Feb 7, 2022
Asthma Trial (mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID, Mometasone furoate MDI (MF MDI) 200 mcg,
Completed
- Asthma
- mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
- +3 more
- (no location specified)
Feb 7, 2022
Asthma Trial (Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI, Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5
Completed
- Asthma
- Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI
- Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI
- (no location specified)
Feb 7, 2022
Pulmonary Disease, Chronic Obstructive Trial in London (CHF1535, Formoterol fumarate)
Completed
- Pulmonary Disease, Chronic Obstructive
- CHF1535
- Formoterol fumarate
-
London, United KingdomUCL Medical School
Oct 28, 2021
COPD Trial in Berlin-Spandau (CHF5993, CHF1535, Matched )
Recruiting
- Chronic Obstructive Pulmonary Disease
- CHF5993
- +2 more
-
Berlin-Spandau, Berlin Spandauer Damm, GermanyPAREXEL International GmbH Early Phase Clinical Unit Berlin
Jan 21, 2022